Skip to content
Takeda’s dengue vaccine approved for use in the EU
Takeda announced the European Commission (EC) authorized the company’s new dengue vaccine for ...
Read More
U.S. punts decision on COVID IP waiver to 2023
Could the Office of the U.S. Trade Representative’s (USTR) position on the COVID ...
Read More
Bivalent COVID boosters are available – here’s why you should get one
The Centers for Disease Control and Prevention (CDC) has released new data demonstrating ...
Read More
How Dobbs v. Jackson is affecting vaccine innovation
Dobbs v. Jackson has had a ripple effect across healthcare—from increasing the danger ...
Read More
Nkarta, Novartis announce positive data in cancer treatment trials
Positive results in trials of cancer treatments were announced by the biotech firms ...
Read More
COVID-19 forced us to reimagine the pharma supply chain – and that’s a good thing
“The pandemic has exposed our country’s dependence on other countries for essential prescription ...
Read More
EDITORS' CHOICE
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the Board ...
Read More
LATEST NEWS
BIO Events
PACE: How 340B outgrew its goal and stopped helping patients
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check. Initially ...
Federal Policy
BIO CEO John Crowley tells Senate how to support biotech
Maintaining America’s biotechnology leadership requires Food and Drug Administration (FDA) modernization as well as Congressional action to reauthorize a program supporting rare disease research and ...
Health
A legacy of love, leadership, and liberation: Tigerlily’s next chapter
October is Breast Cancer Awareness Month, and to mark the occasion, Bio.News has partnered with the Tigerlily Foundation to explore how they developed their advocacy. ...
BIO Events
PACE: CDER director discusses faster approval, FDA morale with BIO CEO John F. Crowley
The FDA is hiring reviewers and finding ways to expedite drug approval, Dr. George Tidmarsh, Director of the Food and Drug Administration (FDA) Center for ...
BIO Events
BIO PACE 2025: Patients need to ensure state policies enable access to medicine
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures will drive many of the ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
BIO PACE 2025: Patients need to ensure state policies enable access to medicine
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures ...
Read More
International
Bio's View
Putting Americans First: Importing European prices means importing European systems and values
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based ...
Read More
